SHERIDAN, WYOMING - April 12, 2026 - Early-stage medtech companies that lost access to federal competitive grant funding when SBIR and STTR program authorization lapsed on April 12, 2026, now face a clearer path to restored capital after both chambers of Congress advanced reauthorization legislation. The Senate passed the measure first, followed by House passage of S. 3971, the Small Business Innovation and Economic Security Act, on April 12, 2026, bringing the programs within reach of full restoration pending presidential signature.
What lapsed and why it matters
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs channel competitive grants through 11 federal agencies - including the National Institutes of Health, the National Science Foundation, and the Department of Defense - directly to small businesses conducting early-stage research and development. For medtech startups, these grants often represent the only non-dilutive capital available before a product reaches the commercial or venture-funding threshold.
Authorization for both programs expired April 12, 2026. The lapse created a funding gap during a period when startups were advancing device concepts, planning pivotal studies, and preparing regulatory submissions. With no active program, federal agencies could not issue new SBIR or STTR awards, stalling projects that depend on this form of government-backed seed financing.
Scope of industry dependence on SBIR and STTR
AdvaMed, the Medtech Association, reports that the majority of its more than 600 member companies are emerging and small businesses, organized under the AdvaMed Accel division. A survey of Accel members found that 89 percent had applied for SBIR or STTR grants, and 31 percent had successfully secured funding - figures that illustrate how structurally embedded these programs are in early-stage medtech development pipelines.
Small medtech businesses face a well-documented funding gap: commercial investors typically require clinical evidence or near-term revenue visibility before committing capital, yet generating that evidence requires R&D expenditure that startups cannot self-fund. SBIR and STTR grants bridge this gap by funding the proof-of-concept and feasibility work that makes subsequent private investment viable. Without program continuity, that bridge disappears, and device development timelines lengthen or collapse entirely.
Legislative path and bipartisan support
Senate passage, led by Sen. Joni Ernst as chair of the Senate Committee on Small Business and Entrepreneurship, and Sen. Ed Markey as ranking member, established the legislative vehicle. On the House side, Rep. Roger Williams, chairman of the House Committee on Small Business, Rep. Lydia Velázquez as ranking member, Rep. Brian Babin, chairman of the House Committee on Science, Space and Technology, and Rep. Zoe Lofgren as ranking member, drove the bill through the chamber. The bipartisan structure of the effort - spanning both small business and science-focused committees - reflects the cross-jurisdictional nature of federal innovation grant programs.
AdvaMed president and CEO Scott Whitaker identified the Senate vote as arriving at a critical juncture, noting that the SBIR and STTR programs advance U.S. healthcare innovation, generate high-quality jobs, and support patient access to next-generation devices. House passage on March 17 converted the Senate action into a bicameral agreement, with the restored programs now pending final enactment.
Business impact
Startup founders and early-stage R&D teams whose grant applications were paused or rejected during the lapse period can now plan around a restored funding cycle. For companies in feasibility-stage device development - particularly those targeting NIH or NSF grant windows - reauthorization reopens application timelines that were effectively frozen for more than five months. Teams should reassess their grant calendars and resubmit or initiate applications as agency award cycles resume.
Venture capital and angel investors evaluating pre-revenue medtech companies will encounter a materially different risk profile once SBIR and STTR funding flows again. Startups with active or pending federal grants carry reduced burn rates and independent validation of technical merit, both of which affect valuation and deal structuring. Investment committees assessing 2026 medtech portfolios should factor program restoration into due diligence assumptions for seed and Series A candidates. Corporate development teams at larger medtech firms that monitor the startup ecosystem for acquisition or licensing targets will also find a more active early-stage pipeline as grant-dependent development programs resume forward progress.